Israeli researchers have conducted clinical trials seeking to demonstrate that pain can be effectively relieved using targeted micro-doses of THC.
The study suggests that using a Selective-Dose Inhaler three to four times per day can relieve pain with a dose of just 500 micrograms of THC, one of the main chemical compounds found in cannabis.
Tel Aviv-based Syqe Medical produces the Selective-Dose Inhaler.
The study concluded that using the inhaler delivers significantly low and precise doses of THC, allowing the administration of inhaled cannabis-based medicines according to high pharmaceutical standards.
This can produce safe and effective analgesia in patients with chronic pain, researchers reported.
The placebo-controlled, double-blind, multi-dose study was conducted at Rambam Hospital in Haifa and led by Prof. Elon Eisenberg, Dean of the Faculty of Medicine at the Technion-Israel Institute of Technology. The findings were published in the European Journal of Pain.
“We were very surprised to see that a modest 500 microgram increment in the dose almost doubled the psychoactive effect," said Syqe CEO Perry Davidson.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.